1/ Need a reason to register for the EMSP Awareness Run 2026? Here are three. 🧵 #EMSPRun26

Only 48% of people with MS are in work across the European countries that report data. MS is usually diagnosed between 20 and 40 — peak career years. Our CEO @Lili_Bxl speaks on brain health and employment today at #IFDM2026 in Edinburgh. #MultipleSclerosis

Running faster isn't only about training harder. It's about wasting less. Part two of coach Guillaume Lodini's #EMSPRun2026 series: technique — posture, stride and breathing. Register 👉️ buff.ly/W1v57ES @eumsyouth

The hardest run of the year isn't the marathon. It's the first one back after summer. Join coach Guillaume for a three-part series to get you ready for #EMSPRun2026. Part one: the three pillars of marathon prep: consistency, intervals, strength Register: bit.ly/4zSwukV

Meet Eline-Sofie Lende Her first MS attack came working her shift on a hospital ward. She was 23 This October she runs the Antwerp Marathon with the EMSP Team, fundraising for young people living with MS, NMOSD and MOGAD. Join her: bit.ly/4zSwukV #MSRun2026 @eumsyouth

EMSP is heading to @ACTRIMS in October! We'll be carrying the voices of people with MS, NMOSD and MOGAD into Patient Community Day on 23 Oct and you'll find us at our booth all week. Come talk MS Barometer, Research and advocacy for patient community. buff.ly/c7N5XFX

🧠 New MedTalk on AI in EBV-MS! Discover how AI could unlock new insights into MS and support personalised treatments. 🎥 Watch: buff.ly/pUTLf9q 📖 Read: buff.ly/LT00jN4

IMMUTOL is featured in Insight magazine’s “Rethinking Health: Transforming Prevention, Treatment and Care” edition. Discover how IMMUTOL is exploring immune reprogramming to transform the future of autoimmune disease treatment. buff.ly/hr3tzge

EMSP's first strategic meeting with our newly elected Executive Committee has wrapped up! 💙 Two days of meaningful discussions, shared vision, and renewed commitment to serving the MS, NMOSD & MOGAD communities across Europe #MS #NMOSD #MOGAD #StrongerTogether

Time matters in MS: early diagnosis + timely treatment prevent irreversible disability. Yet access across Europe remains a postcode lottery. This #WorldBrainDay, the 7th #MSBarometer is underway — now including NMO & MOGAD for the first time. 📊emsp.org/projects/ms-baromet…

🧬 New insights into EBV and multiple sclerosis (MS) EBV-MS researchers found that MS is linked to stronger EBV-specific immune responses, reduced by anti-CD20 therapy. The findings support future EBV-targeted vaccines and antiviral approaches. Read here: buff.ly/LOEmoR0

🧬 New BEHIND-MS research: Family history of MS is linked to genetic risk and traits related to vitamin D and body weight, but not faster early disease progression. 📖 Van Luijn M. et al. (2026) #MultipleSclerosis #MSResearch #BEHINDMS #HaDEA

Thank you to our vibrant @eumsyouth community for their active participation, endless energy, and valuable contributions in making these monthly catch-ups so delightful! See you in the next one. #randomcoffee #ypn @annarevillab @lili_bxl @PPuljic92

Nutrition can't cause MS. And it can't cure it. But it shapes fatigue, bowel symptoms, inflammation, cardiovascular risk — and quality of life. Dietitian Sophie Pratt and Marjolijn Oranje on what actually works, in the new Let's Talk MS. 🎧 bit.ly/3RuVUDS #MSPodcast

Can we prevent MS before symptoms appear? As part of the WISDOM project, Prof. Bernhard Hemmer explores how EBV, genetics and biomarkers could help identify risk earlier. Read more: buff.ly/AQDPzwW #WISDOM #HorizonEU

Yesterday EMSP presented the #MSBarometer at the European Charcot Foundation's MS Initiatives meeting. A first for 2025–2027: NMO & MOGAD join MS in the Barometer — long-missing pan-European data, finally in view. Thanks #EuropeanCharcot for the warm exchange! #MSBarometer2027

🧬 New EBV-MS study: rituximab shows comparable effectiveness and safety to ocrelizumab in early MS, supporting more affordable access to high-efficacy treatment. 📖 buff.ly/QxpQvis #MSResearch #EBVMS #HorizonEurope

🎙️ New MedTalk: Why do only some people with EBV develop MS? Explore the roles of genetics, EBV strains, and AI in advancing MS research. 📖 buff.ly/THCgqaI ▶️ buff.ly/WBU4fZT #EBVMS #HorizonEurope #MSresearch

516 patients per nurse That's the average caseload MS nurses reported in our 2024 survey. Join our live webinar on smarter workload strategies for MS nurses, with Mavis Ayer (UK) & Francesco Pastore (Italy). 🗓 Wed 8 July, 4pm CEST Register: msnursepro.org/webinars/4278…